Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2024

The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.11 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 25.6%. The growth during the historical period can be ascribed to factors such as diabetes and metabolic syndrome, awareness and screening initiatives, limitations in liver biopsy, regulatory backing, a transition towards personalized medicine, and clinical trials in nonalcoholic steatohepatitis (NASH).

The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The growth anticipated in the forecast period can be linked to the emergence of new therapies, the extension of precision medicine approaches, initiatives by patient advocacy groups, the integration of multi-omics data, and heightened patient engagement. Key trends in the forecast period encompass telemedicine and remote monitoring, innovative diagnostic platforms, global research collaborations, technological advancements in biomarker discovery, the incorporation of artificial intelligence (AI), and the inclusion of imaging biomarkers.

The anticipated increase in the prevalence of liver cancer is expected to drive the growth of the non-alcoholic steatohepatitis biomarkers market. Liver cancer, whether originating in the liver itself (primary liver cancer) or spreading from other parts of the body (secondary or metastatic liver cancer), necessitates the use of non-alcoholic steatohepatitis (NASH) biomarkers for early detection, disease progression monitoring, and treatment response assessment. These biomarkers also provide prognostic information, reducing the reliance on invasive procedures. For example, recent studies, as reported by the Journal of Hepatology in October 2022, attribute about 56% of liver cancer cases to the hepatitis B virus (HBV). Consequently, the growing prevalence of liver cancer is a key factor propelling the non-alcoholic steatohepatitis biomarkers market.

The increasing demand for personalized medicine is poised to fuel the growth of the non-alcoholic steatohepatitis biomarkers market. Personalized medicine involves tailoring medical decisions, interventions, and drug therapies to individual patients. In the context of non-alcoholic steatohepatitis (NASH) biomarkers, personalized medicine facilitates precise and individualized diagnosis, the development of tailored treatment strategies, optimized drug selection, treatment response monitoring, and minimization of adverse effects. Reports from October 2022 indicate over 75,000 genetic testing products and 300 personalized medicines, highlighting the growing demand for personalized medicine and its role in driving the non-alcoholic steatohepatitis biomarkers market.

Technological advancements have emerged as a prominent trend in the non-alcoholic steatohepatitis biomarkers market, with major companies focusing on innovative solutions to enhance their market position. In October 2022, GENFIT and LabCorp entered a five-year exclusive licensing deal for GENFIT's NIS4 technology, a multi-biomarker-based algorithm designed to identify patients at risk of non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis. LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada. This partnership aims to provide widespread access to healthcare professionals, demonstrating the importance of technological advancements in driving the non-alcoholic steatohepatitis biomarkers market.

Major companies in the non-alcoholic steatohepatitis biomarkers market are also focusing on innovative products, such as NASHnext, to boost revenues. NASHnext, launched by Genfit S.A. in May 2021, utilizes NIS4 technology, a patented diagnostic tool for detecting NASH and significant fibrosis. This revolutionary blood-based molecular biomarker test helps identify patients with NASH and assess the severity of the condition. The test combines four distinct NASH-associated biomarkers to provide a comprehensive score representing both fibrosis and NASH activity, aiming to transform the diagnosis and management of nonalcoholic steatohepatitis (NASH).

In June 2022, Novo Nordisk A/S partnered with Echosens SA to promote early diagnosis of non-alcoholic steatohepatitis (NASH) and raise awareness among patients, medical professionals, and other stakeholders. Echosens SA, a France-based manufacturer, specializes in therapeutic monitoring and diagnostic devices.

Major companies operating in the non-alcoholic steatohepatitis biomarkers market report are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Conatus Pharmaceuticals, Immuron Ltd, Metacrine.

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-alcoholic steatohepatitis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of NASH biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others. Hepatic fibrosis biomarkers are specifically designed to assess hepatic fibrosis, an exaggerated wound healing response leading to excessive connective tissue formation in the liver. These biomarkers are utilized in the treatment of various diseases, including hypertension, heart disease, high blood lipids, type 2 diabetes, and obesity. NASH biomarkers find applications across various end-users, including research institutes and academics, diagnostic centers, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics, among others.

The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports that provides non-alcoholic steatohepatitis biomarkers market statistics, including non-alcoholic steatohepatitis biomarkers industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis biomarkers market share, detailed non-alcoholic steatohepatitis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. This non-alcoholic steatohepatitis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.